Non-compaction cardiomyopathy – brief review

Oana Mirea  
*Craiova University of Medicine and Pharmacy, Department of Cardiology, Craiova, Romania*

Mihaela Berceanu  
*Craiova University of Medicine and Pharmacy, Department of Cardiology, Craiova, Romania*

Anca Constantin  
*Craiova Emergency County Hospital, Department of Cardiology, Craiova, Romania*

Mirela Mănescu  
*Victor Babeș Hospital, Department of Cardiology, Craiova, Romania*

Georgică Costinel Târtea  
*Craiova University of Medicine and Pharmacy, Department of Physiology, Craiova, Romania, georgetartea@gmail.com*

See next page for additional authors

Follow this and additional works at: [http://scholar.valpo.edu/jmms](http://scholar.valpo.edu/jmms)

Part of the Cardiology Commons, and the Diseases Commons

---

Recommended Citation

Mirea, Oana; Berceanu, Mihaela; Constantin, Anca; Mănescu, Mirela; Târtea, Georgică Costinel; Donoiu, Ionut; Militaru, Constantin; and Istrătoaie, Octavian (2017) "Non-compaction cardiomyopathy – brief review," *Journal of Mind and Medical Sciences: Vol. 4 : Iss. 2 , Article 5*.  
DOI: 10.22543/7674.42.P115124  
Available at: [http://scholar.valpo.edu/jmms/vol4/iss2/5](http://scholar.valpo.edu/jmms/vol4/iss2/5)

This Review Article is brought to you for free and open access by ValpoScholar. It has been accepted for inclusion in Journal of Mind and Medical Sciences by an authorized administrator of ValpoScholar. For more information, please contact a ValpoScholar staff member at scholar@valpo.edu.
Non-compaction cardiomyopathy – brief review

Cover Page Footnote
All authors contributed equally to the manuscript.

Authors
Oana Mirea, Mihaela Berceanu, Anca Constantin, Mirela Mănescu, Georgică Costinel Târtea, Ionuț Donoiu, Constantin Militaru, and Octavian Istrătoae
Review

Non-compaction cardiomyopathy – brief review

Oana Mirea¹, Mihaela Berceanu¹, Anca Constantin², Mirela Mănescu³, Georgică C. Târtea²,⁴, Ionuţ Donoiu¹, Constantin Militaru¹, Octavian Istrătoaie¹

¹Craiova University of Medicine and Pharmacy, Department of Cardiology, Craiova, Romania
²Craiova Emergency County Hospital, Department of Cardiology, Craiova, Romania
³Victor Babeş Hospital, Department of Cardiology, Craiova, Romania
⁴Craiova University of Medicine and Pharmacy, Department of Physiology, Craiova, Romania

Abstract

Left ventricular non-compaction cardiomyopathy is a genetic disorder characterized by the presence of two myocardial layers with numerous prominent trabeculations and deep inter-trabecular recesses that communicate with the ventricular cavity. The diagnosis is often challenging because excessive trabeculations may also be a normal finding in performance athletes and black people.

Echocardiography is the gold standard for diagnosis of this condition, but other useful diagnostic techniques may include cardiac magnetic resonance imaging, computed tomography, and contrast ventriculography. Moreover, newer echocardiographic methods such as three-dimensional imaging and speckle tracking analysis promise to improve the diagnosis of left ventricular non-compaction cardiomyopathy. The purpose of this paper is to review the pathogenesis, diagnosis, and management of this disease.

Keywords: cardiomyopathy and heart failure; echocardiography, genetics

Correspondence should be addressed to: Ionuţ Donoiu; e-mail: ionut.donoiu@umfcv.ro
Introduction

Left ventricular non-compaction (LVNC) or ‘spongy myocardium’ is a congenital disorder characterized by the presence of a thin epicardial layer and an excessively trabeculated endocardial layer. This particular spongy aspect of the myocardium was first described more than eight decades ago in association with aortic atresia and coronary-to-chamber fistula during the autopsy of a newborn with complex congenital abnormalities (1). The introduction of two-dimensional echocardiography facilitated the evaluation of left ventricle (LV) anatomy and continuously increased the number of cases diagnosed. In 1984 Engberding described the presence of ‘sinusoids’ within the LV, but it was not until 1990 that the first diagnostic echocardiographic criteria of LVNC were proposed and terminology was established (2, 3).

Despite current developments in cardiac imaging and genetic diagnostic techniques, it is yet controversial whether left ventricular non-compaction cardiomyopathy is a distinct cardiomyopathy or a morphologic feature shared by different types of cardiomyopathy (4). Recent data, for example, have found that a significant proportion of asymptomatic individuals free from cardiovascular disease met all currently used magnetic resonance imaging (MRI) diagnostic criteria for LVNC, suggesting that the condition is an anatomical phenotype rather than a distinct cardiomyopathy (5). To add to the controversy, non-compacted myocardium has been categorized as unclassified cardiomyopathy by the European Society of Cardiology (ESC) in the recently published report on the definition and classification of cardiomyopathies (6), whereas the American Heart Association (AHA) classifies it as a primary genetic cardiomyopathy (7) (Figure 1).

Discussion

Prevalence

The prevalence of LVNC in the general population remains unknown, although in echocardiographic series it is reported around 0.14-1.3%. Isolated ventricular non-compaction has an incidence of 0.01-0.26% in observational studies (8, 9). In a pediatric population with any type of primary cardiomyopathy, LVNC was diagnosed in 9.2%, being the most frequent form after dilated and hypertrophic cardiomyopathy (10). Left ventricular non-compaction in children is often associated with anatomical abnormalities such as septal or atrial defects, congenital aortic stenosis, and aortic coarctation, although studies have failed to demonstrate any direct relation among these conditions. Furthermore, non-compacted myocardium has been found in patients with neuromuscular diseases such as Becker muscular

Figure 1. Classification of primary (predominantly involving the heart) cardiomyopathies according to ESC and AHA. AHA, American Heart Association; ARVD, Arrhythmogenic right ventricle dysplasia; CM, cardiomyopathy; DCM, dilated cardiomyopathy; ESC, European Society of Cardiology; HCM, hypertrophic cardiomyopathy; LVNC, left ventricle non-compaction.
Non-compaction cardiomyopathy
dystrophy, Friedrich ataxia, myotonic dystrophy, or mitochondrial diseases.

Nevertheless, published rates may well underestimate the prevalence of LVNC. Better echocardiographic imaging and LVNC awareness will likely lead to a better recognition of this pathology.

Pathogenesis

The mechanisms of non-compaction are not yet fully understood. The main morphogenetic anomaly is represented by the cessation of compaction of ventricular endomyocardium during intrauterine development. If this process does not progress normally, the LV develops as a two-layered structure, with a thick non-compacted endocardial layer and a thin compacted epicardial layer, mostly observed in the inferior, lateral and apical segments.

During myocardial embryonic development, the muscular fibers lose their connections, resulting in a weak fiber network, with recesses that connect the myocardial wall with the ventricular cavity. Only in the 5th or 6th week of gestation does this fiber and intertrabecular recesses network begin the compaction process, starting from the base towards the apex and from the endocardium to the epicardium. This process implies the secretion of endothelial growth factors, such as neuregulins and angiopoietins. For reasons still unknown, this process ceases in patients with LVNC, resulting in a thick non-compacted endomyocardial layer with prominent trabeculae and deep recesses that communicate with the LV cavity and a thin compacted epicardial layer. This embryologic hypothesis is supported by the fact that LVNC is frequently associated with other congenital heart abnormalities (11). Other theories suggest that ventricular non-compaction might be the consequence of a cardiac neuropathy or the result of a malfunction of gap junctions (12).

The trabecular phenotype in LVNC can also develop during adulthood as a response to left ventricular overload. In one large-scale study, excessive trabeculation of the LV was found in up to 18% of highly trained athletes. Nonetheless, only 0.9% of these athletes also presented with ECG changes and echocardiographic signs of systolic function depression (13). Development of the ‘de novo’ hypertrabeculation has been observed in more than 25% of pregnant women and is related to LV overload and mechanisms of physiological adaptation to pregnancy. A similar anatomical aspect was described in patients suffering from sickle cell disease and chronic renal failure (14) due to an exaggerated response to the increase in preload. These examples challenge the embryogenesis theory and suggest involvement of acquired pathogenetic mechanisms or epigenetic factors. Given these considerations a recent review recommends cautious diagnostic labeling of LVNC as a cardiomyopathy (15).

Genetics

LVNC is a heterogeneous, familial, or sporadic genetic disorder. Genetic studies have strongly suggested that the disease has a pattern of inheritance (18% to 50% of cases are familial). The family form appears more frequently in adults with isolated LVNC than in the case of children, and it can be autosomal dominant, X-linked, or mitochondrial. Mutations of genes that code sarcomeric proteins (ACTC1 - cardiac alpha actinin, MYH7 - beta myosin heavy chain, TNNT2 - Troponin T, G4.5-tafazzin - responsible for Barth syndrome, TMP1-tropomyosin, MYBPC3 - binding protein C) (16-18), cytoskeletal and Z-line components (LDB3 - binding protein 3) (19), nuclear envelope proteins (LMNA-laminin A/C) (20) and ion-channels (SNC5A - RYR2) (21) have been identified in patients with ventricular non-compaction. Moreover, the hypertrabecular and non-compacted aspect of the left ventricle has also been associated with monogenic syndromes such as Danon disease (22) or, in a few cases, Anderson-Fabry disease (23). Other genetic conditions
that coexist with the spongious feature of the LV myocardium are Duchenne muscular dystrophy (24), mitochondrial myopathies (9), chromosomal disorders, and congenital heart disease. Specific mutations in genes of the Notch1 pathway (mindbomb homolog 1) in mice and humans leading to dysregulated signaling and hypertrabeculation and non-compaction (25), as well as mutations in the G4.5 gene that result in a severe, infantile, X-linked form of LVNC, suggest strongly that LVNC is a cardiomyopathy.

It is therefore both important and challenging to distinguish whether LVNC is an isolated cardiomyopathy or an anatomical characteristic associated with other cardiac disorders. Previous studies suggest that a detailed analysis of the family background in patients diagnosed with LVNC is justified.

**Physiopathology**

The two myocardial layers and the trabeculae are vascularized by the epicardial coronary arteries and the intertrabecular recesses receive blood from the ventricular cavity. Endocardial hypoperfusion arises because of a discrepancy between the number of capillaries and the myocardial mass. As a consequence of ischemia, fibrosis will expand progressively and will ultimately determine left ventricular systolic function depression which will predispose to ventricular arrhythmias. LVNC is a potential thromboembolic disease due to the blood stagnation in the intertrabecular recesses which predisposes to clot formation, which can embolize in systemic circulation.

**Imaging and Diagnosis**

A multimodal diagnostic approach is the current recommendation for LVNC diagnosis. Echocardiography, although dependent on the echocardiographer’s skills and the echocardiographic window, remains the primary diagnostic method. Other imaging methods such as cardiac MRI can diagnose the pathology, when echocardiographic examination is suboptimal.

**Echocardiographic diagnosis criteria**

Transthoracic bidimensional echocardiography (2D-TTE) is the method of choice for diagnosing LVNC (Figure 2-4). Three basic echocardiographic criteria have been proposed to define LVNC: a thick myocardium with a non-compacted layer and a compacted one; prominent trabeculations; and deep endomyocardial recesses.

Several echocardiographic derived algorithms for diagnosing LVNC have been proposed (3, 26, 27). The first echocardiographic criterion has defined ventricular wall non-compaction as the ratio $X / Y < 0.5$, where $X$ represents the distance from the epicardial surface to the trabecular recesses and $Y$ is the distance from the epicardial surface to the peak of trabeculae, measured in parasternal short axis for the apex and apical sections for the left ventricular free wall (3). Others have proposed a ratio between non-compacted and compacted myocardium greater than 2:1 at end systole, in apical short axis section, in the absence of other cardiac disorders (26) for the diagnosis of LVNC. The trabeculae are usually situated at the apex / lateral wall, medium wall / inferior wall of the left ventricle. Most of the non-compacted segments are hypokinetic. Stollberger et al. (27) defined LVNC as the presence of more than three trabeculae in the left ventricular wall, with trabeculae situated at the apex, visible in a single imaging plan. The flow between the inter-trabecular recesses can be identified by using the color Doppler method. A fourth criterion has been proposed by Belanger et al. (28), who diagnosed LVNC using planimetric echocardiography to measure the trabeculae in apical 4 chambers section. They divided the patients by the area of left ventricular non-compaction into 3 groups: mild (< 2.5 cm²), moderate (2.5-4.9 cm²) and severe (> 5 cm²). Based on a study on 380 patients,
Non-compaction cardiomyopathy

15.8% were diagnosed with LVNC. However, their criteria have not been validated as there was no correlation with the modified Jenni et al. criteria.

**Figure 2.** Bidimensional transthoracic echocardiography, short axis view of the left ventricle apex. Note the excessive trabeculation in the infero-posterolateral region. Red line indicates the distance from the epicardial line to the beginning of the trabeculae (7 mm) and yellow line marks the thickness of the trabeculae (17 mm).

**Figure 3.** Bidimensional transthoracic echocardiography, apical 3-chamber view (the same patient as in figure 2). The hypertrabeculation can be observed in the mid and apical region of the posterior wall (yellow arrows).

Newer echocardiographic techniques such as tissue Doppler imaging, strain rate imaging, and speckle tracking imaging are now available for the diagnosis of LVNC. Global longitudinal strain was found to be lower in subjects with LVNC compared with healthy controls even in the presence of normal systolic/diastolic function (29). A recent study also demonstrated that while in normal individuals and subjects with hypertrophic cardiomyopathy there is a significant increase in longitudinal deformation from base to apex, in subjects with LVNC, apical strain was only mildly and not significantly increased (30). Three-dimensional echocardiography and contrast echocardiography may bring additional valuable data to the dimensional assessment in patients with LVNC by providing an accurate evaluation of the number of trabeculae, compacted segments, and intertrabecular recesses (31).

**Cardiac Magnetic Resonance criteria**

Cardiac magnetic resonance imaging is continually evolving and may contribute to a more accurate identification of LVNC. Cardiac MRI is particularly useful in patients in whom the apex is difficult to visualize with echocardiography. Two sets of MRI criteria proposed by Petersen in 2005 (32) and Jacquier in 2010 (33) are used for LVNC diagnosis. Petersen et al. defined a ratio between non-compacted/compacted layer > 2.3 measured in end-diastole as a cutoff for LVNC. Jacquier et al. calculated the LV trabecular mass in short axis views in end-diastole and concluded that a trabecular mass > 20% was predictive for LVNC.

Captur et al. (34) described a recent cardiac MRI technique, based on fractal analysis, which does not rely
on ‘classical’ compacted/non-compacted ratio. A fractal dimension > 1.3 gave the optimal prediction for LVNC.

Late gadolinium enhancement (LGE) of trabeculae has also been observed in LVNC. LGE distributions in patients fulfilling LVNC criteria can be very heterogeneous, which may suggest several distinct cardiomyopathic processes that are responsible for LVNC. Small areas of myocardial fibrosis have also been observed in patients with preserved systolic function (35).

Other diagnostic imaging

Computed tomography (CT) is an alternative method of diagnosing LVNC if the echocardiogram is non-diagnostic or unavailable (36). Positron emission tomography (PET), which quantitatively evaluates myocardial blood flow and coronary flow reserve, may be used to assess microcirculatory dysfunction ultimately responsible for the wall motion abnormalities (37).

Differential diagnosis

As there is no diagnostic gold standard, LVNC is frequently underdiagnosed or misdiagnosed as hypertrophic or dilated cardiomyopathy. The differential diagnosis should include: apical hypertrophic cardiomyopathy, left ventricular hypertrophy, dilated cardiomyopathy, arrhythmogenic left ventricular dysplasia, myocardial/endocardial fibroelastosis, cardiac tumors, left ventricular apical thrombus, normal heart with left ventricular prominent trabeculations (less than 3 trabeculations in echocardiography). Usually, a careful echocardiography study by a trained examiner will provide the diagnosis. A major challenge is to differentiate LVNC with dilated left ventricle from dilated cardiomyopathy.

Management of LVNC

Currently no specific guidelines exist for the treatment of LVNC. Clinical management of LVNC depends on the presence or absence of cardiac dysfunction or arrhythmias. Patients with normal LV size and function will undergo clinical monitoring, whereas symptomatic patients with LV dilation and dysfunction or hypertrophy may be managed according to their clinical needs and corresponding guidelines. In later stages, recommendations for treatment follow the international guidelines of heart failure management. Treatment usually requires the combination of beta-blockers, ACE inhibitors/ARB, diuretics, and aldosterone antagonists.

The main complications related to LVNC are systemic thromboembolic events, arrhythmias, progressive heart failure, and sudden cardiac death. Oral anticoagulation is a debated issue in the prevention of thromboembolic complications. The question that arises is whether anticoagulation should be given independently of arrhythmias or LV dysfunction for primary prevention of embolic episodes, or only in the presence of LV dysfunction, arrhythmias, prior embolic events, or proven atrial or ventricular thrombi. Left ventricular clot and documented atrial fibrillation are clear situations when oral anticoagulation should be used. For patients that do not fall into either of these categories, Bennet et al. suggest a risk assessment using the CHADS2/CHA2DS2-Vasc scores as guidance and a discussion with the patient regarding the risks and benefits of anticoagulation (38).

Sudden cardiac death is another concerning complication of LVNC. Patients should be periodically evaluated by Holter ECG for ventricular arrhythmias. The incidence of ventricular arrhythmias rises from 2% to 62% in patients with LVNC. Those with sustained ventricular arrhythmia and those who have experienced an episode of cardiac arrest require ICD implantation.

Although data regarding anti-arrhythmic therapy are scant, recent research supports the idea of early aggressive therapy, including defibrillator and evaluation for cardiac transplant, for patients with bundle branch
Non-compaction cardiomyopathy block, increased left ventricle end-diastolic diameter, or permanent or persistent atrial fibrillation in III-IV NYHA functional class.

Echocardiographic screening is also recommended for family members, given that the symptoms are variable and the risks include heart failure and sudden cardiac death. Genetic testing for LVNC does not change clinical management of the disease; however, it may be helpful for confirming diagnosis in family members.

**Prognosis**

LVNC is associated with high morbidity and mortality rates although prognosis has significantly improved in recent years through earlier diagnosis and use of heart failure medications and device therapy. In one Swiss cohort, 35% of patients suffered early death, 53% required hospitalization for congestive heart failure, 41% had ventricular tachyarrhythmia, 12% required ICDs, and 12% required heart transplantation over 44 months of follow-up (39). In another recent study, among 45 patients referred to a cardiomyopathy center, survival free of transplantation was 97% over 4 years of follow-up (40).

**Conclusions**

LVNC is a rare cardiomyopathy associated with significant morbidity and mortality. The diagnosis remains challenging and a multimodal diagnostic approach is currently recommended. The classical clinical presentation is the triad of heart failure, arrhythmias, and embolic events. There are no consensus guidelines for the management of these patients.

**Acknowledgments**

All authors contributed equally to the manuscript.

**References**

7. Maron BJ, Towbin JA, Thiene G, Antzelevitch C, Corrado D, Arnett D, Moss AJ, Seidman CE, Young JB; American Heart Association; Council on Clinical Cardiology, Heart Failure and
Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; Council on Epidemiology and Prevention. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. *Circulation* 2006; 113(14): 1807–16. PMID: 16567565, DOI: 10.1161/CIRCULATIONAHA.106.174287


